The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1167
October 13, 2003
View Complete Issue         Table of Contents 2019 
Lp-PLA2: a New Marker of Vascular Risk
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lp-PLA2: a New Marker of Vascular Risk
October 13, 2003 (Issue: 1167)
Lipoprotein associated phospholipase A2 (Lp-PLA2), an enzyme involved in the repair of oxidative damage to lipoproteins, causes release of inflammatory mediators associated with atherosclerosis. A new assay, PLAC (diaDexus, Inc.), is now available to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lp-PLA2: a New Marker of Vascular Risk
Article code: 1167b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.